HS-10516 plus lenvatinib for advanced clear-cell kidney cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, open-label Phase Ib/II study gives HS-10516 in combination with lenvatinib to adults with advanced clear-cell renal cell carcinoma who progressed after ≥1 prior systemic therapy. It begins with a dose-exploration safety lead-in using 28-day treatment cycles where 3–6 participants per dose level are enrolled to monitor dose-limiting toxicities and PK/PD. A Safety Review Committee will decide dose escalation or de-escalation and PK expansion cohorts (up to 12 participants each) may be added at suitable dose levels. After safe dose levels are identified, one or two dose cohorts will move to a proof-of-concept Phase II stage enrolling up to 40 participants per cohort to further test efficacy and safety until disease progression or other discontinuation criteria are met.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Men or women aged more than or equal to (≥) 18 years.
2. Histologically confirmed unresectable, locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) with disease progression during or after receiving ≥1 prior line of systemic therapy in the advanced setting.
3. Patients have at least one target lesion according to RECEST 1.1. The requirements for target lesions are: measurable lesions without local treatment such as irradiation, or with definite progress after local treatment, with the longest diameter ≥ 10 mm in the baseline period (in case of lymph nodes, the shortest axis ≥ 15 mm is required). Patients with only brain and/or bone lesions as target lesions will not be included.
4. ECOG performance status was 0-1 and did not deteriorate in the previous 2 weeks.
5. Estimated life expectancy greater than (\>) 12 weeks.
6. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 12 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.
7. Females must have the evidence of non-childbearing potential
8. Sign informed consent form.

Exclusion Criteria:

1. Prior or Current Treatments:

   1. Previous or current use of hypoxia-inducible factor inhibitors.
   2. Previous or current use of lenvatinib.
   3. Use of Chinese herbal medicine with antitumor indications within 2 weeks prior to the first dose or requirement for such treatment during the study.
   4. Administration of cytotoxic chemotherapy or other systemic antitumor therapies (e.g., endocrine therapy, molecular targeted therapy) within 2 weeks or 5 half-lives (whichever is shorter) prior to the first dose, or requirement for such treatments during the study.
   5. Use of large-molecule antitumor drugs within 4 weeks prior to the first dose or requirement for such treatment during the study.
   6. Use of CYP2C19 strong inhibitors/inducers or narrow therapeutic index sensitive substrates within 7 days prior to the first dose, or requirement for continued use during the study.
   7. Local radiotherapy (except brain radiotherapy; see Criterion 6) within 2 weeks prior to the first dose, or \>30% bone marrow irradiation/large-field radiotherapy within 4 weeks prior to the first dose.
   8. Major surgery (e.g., craniotomy, thoracotomy, laparotomy; Grade 3/4 per Chinese Medical Technical Clinical Application Regulations) within 4 weeks prior to the first dose.
   9. Participation in other interventional clinical trials within 4 weeks prior to the first dose or within 5 half-lives of investigational drugs (whichever is longer).
2. Resting pulse oximetry \<92% at screening.
3. Severe pulmonary dysfunction requiring intermittent/long-term oxygen therapy.
4. Unresolved Grade \>1 toxicities from prior anti-tumor therapy (per CTCAE v5.0).
5. History of second primary malignancy.
6. Known or suspected active CNS metastases/leptomeningeal disease.
7. Inadequate bone marrow reserve or serious organ dysfunction.
8. Severe, uncontrolled, or active cardiovascular disease.
9. Severe or poorly controlled diabetes.
10. Severe or poorly controlled hypertension.

Where it's running

• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Jun Guo
• Email: guoj307@126.com
• Phone: 010-88196358

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VSV-IFNβ-NIS plus ipilimumab and nivolumab for advanced or metastatic clear cell renal cell carcinoma

  This trial adds a virus-based therapy (VSV-IFNβ-NIS) to standard immunotherapy (ipilimumab and nivolumab) to see if it helps people with advanced or metastatic clear cell renal cell cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07510334

• Adding a probiotic to standard immunotherapy for advanced kidney cancer

  This trial tests whether adding MO-03 probiotic to standard immunotherapy helps people with advanced or metastatic clear cell kidney cancer.

  Recruiting at 41 sites Phase 3 SWOG Cancer Research Network · Fayetteville, Arkansas and 40 other locations · NCT07383441

• Nivolumab and ipilimumab with or without EXL01 for advanced or metastatic clear-cell and sarcomatoid renal cell carcinoma

  This trial tests whether adding EXL01, a live Faecalibacterium prausnitzii product, to nivolumab and ipilimumab helps adults with advanced or metastatic clear-cell or sarcomatoid renal cell cancer.

  Recruiting at 2 sites Phase 1 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07128680

• Combining sasanlimab, palbociclib, and axitinib for metastatic kidney cancer

  This test tries a combination of sasanlimab, palbociclib, and axitinib in people with advanced or metastatic clear cell or translocation renal cell carcinoma to see if it works and is safe.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07123090

• Casdatifan plus cabozantinib versus placebo plus cabozantinib for advanced clear cell kidney cancer

  This trial tests whether adding casdatifan to cabozantinib helps adults with advanced or metastatic clear cell kidney cancer who progressed after PD‑1 or PD‑L1 immunotherapy.

  Recruiting at 191 sites Phase 3 Arcus Biosciences, Inc. · Gilbert, Arizona and 190 other locations · NCT07011719

• Genetic testing to choose the best treatment for advanced kidney cancer

  This study is testing if using genetic testing to pick the best treatment can help people with advanced kidney cancer respond better to either a combination of immunotherapy drugs or a mix of immunotherapy and targeted therapy.

  Recruiting at 6 sites Phase 2 Vanderbilt-Ingram Cancer Center · Duarte, California and 5 other locations · NCT05361720

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.